ENDPOINTS

MoonLake's CEO on its looming mid-year pivotal readout in skin disease

MIAMI — MoonLake Immunotherapeutics is expected to have one of the biotech industry's biggest stock-moving clinical readouts around the middle of this year for a pair of Phase 3 trials in a painful inflammatory skin condition ...

Mar 14, 2025 - 10:06
 0
MoonLake's CEO on its looming mid-year pivotal readout in skin disease
MIAMI — MoonLake Immunotherapeutics is expected to have one of the biotech industry's biggest stock-moving clinical readouts around the middle of this year for a pair of Phase 3 trials in a painful inflammatory skin condition ...
Read More

Tags:

Previous Article

Dr. Oz Faces Senators at Confirmation Hearing to Oversee Medicare and Medicaid

Next Article

5 nature-inspired ways to bring joy and wonder into your life this spring

Related Posts

Roche heads to FDA with Gazyva results in a form of lupus

Roche heads to FDA with Gazyva results in a form of lupus

Feb 9, 2025  0

Bristol Myers buys out cell therapy partner 2seventy bio

Bristol Myers buys out cell therapy partner 2seventy bio

Mar 11, 2025  0

Septerna ends Phase 1 trial for hypoparathyroidism drug; Sanofi’s Merilog is approved

Septerna ends Phase 1 trial for hypoparathyroidism drug...

Feb 18, 2025  0